Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL3044295 | 0.95 | ADRB2 (0.57) | ADRB2SMYD2 | |
| SCHEMBL1683019 | 0.94 | ADRB2 (0.58) | ADRB2SMYD2 | |
| SCHEMBL2209783 | 0.93 | ADRB2 (0.59) | ADRB2SMYD2 | |
| SCHEMBL524144 | 0.93 | ADRB2 (0.59) | ADRB2SMYD2 | |
| Bromide SCHEMBL1682997 | 0.93 | ADRB2 (0.59) | ADRB2SMYD2 | |
| SCHEMBL2212570 | 0.93 | ADRB2 (0.60) | ADRB2SMYD2 | |
| SCHEMBL1683056 | 0.92 | ADRB2 (0.53) | ADRB2SMYD2 | |
| SCHEMBL2210692 | 0.87 | SMYD2 (0.52) | ADRB2SMYD2 | |
| SCHEMBL2213469 | 0.87 | SMYD2 (0.52) | ADRB2SMYD2 | |
| SCHEMBL2213235 | 0.86 | ADRB2 (0.62) | ADRB2SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303266-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A 4-HYDROXY-2-OXO-2, 3- DIHYDRO-1, 3-BENZOTHIAZOL-7-YL COMPOUND FOR MODULATION OF BETA2-ADRENORECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| US-20100144606-A1 | COMBINATION 408 | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| WO-2009154562-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A 4-HYDROXY-2-OXO-2, 3- DIHYDRO-1, 3-BENZOTHIAZOL-7-YL COMPOUND FOR MODULATION OF BETA2-ADRENORECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144606-A1 | COMBINATION 408 | NR3C2, PTGER2, LTB4R2 | ADRB2 51/4885SMYD2 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.